Association of fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acyl-coenzyme A synthetase long-chain 4 (ACSL4) expression and human epidermal growth factor receptor 2 (HER2) status with metastasis and survival in breast cancer: a five-year follo

Negar Dinarvand, Morteza Pourfarzam, Mobina Emadi, Mohammadreza Karbalaei Hashemiyan, Reza Azizi

Abstract


Background and purpose: Breast cancer is one of the leading causes of death among women worldwide, with rising incidence rates, particularly in rapidly developing countries such as Iran. This study aimed to investigate the relationship between lipid metabolism enzymes, fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acyl-CoA synthetase long-chain family member 4 (ACSL4), and patient survival, with a focus on their potential role in breast cancer metastasis. In addition, we evaluated the prognostic significance of human epidermal growth factor receptor 2 (HER-2) overexpression in breast cancer patients.

Experimental approach: A total of 52 breast cancer tissue samples were collected from patients at Ordibehesht Clinic in Isfahan, Iran. RNA was extracted and analyzed using qRT-PCR to quantify the expression of FASN, ACLY, and ACSL4. Kaplan-Meier survival curves and log-rank tests were applied to assess survival rates and metastasis.

Findings/Results: The Kaplan-Meier analysis showed an average time to metastasis of 36.18 months. No significant associations were found between metastasis and the expression levels of ACLY, FASN, or ACSL4. In contrast, HER-2 expression was significantly associated with metastasis, underscoring its potential as a critical prognostic marker. Other clinicopathological factors, including tumor grade, stage, size, and receptor status, were not significantly related to metastasis.

Conclusion and implications: Our study highlights the importance of HER-2 as a key prognostic marker in breast cancer and suggests that further research is required to clarify the mechanisms underlying its role in cancer progression.

 

 


Keywords


Breast neoplasms; Fatty acid synthase; ATP citrate lyase; Acyl-CoA synthetase; Receptor, ERBB-2; Neoplasm metastasis; Survival analysis.

Full Text:

PDF

References


Fenga C. Occupational exposure and risk of breast cancer. Biomed Rep. 2016;4(3):282-292.DOI: 10.3892/br.2016.575.

Salimi Z, Fatehifard R, Aghaei M, Panjehpour M. Clinical relevance of circulating biomarkers in breast cancer metastasis detection:" insights from liquid biopsy technology". Res Pharm Sci. 2025;20(5):689-700.DOI: 10.4103/RPS.RPS_138_24.

Zarei M, Bagheri-Saweh MI, Rasolabadi M, Vakili R, Seidi J, Kalhor MM, et al. Breast cancer research in Iran: a scientometric analysis of publications output from 1991 to 2015 in Scopus. Electron Physician. 2017;9(2):3816-3822.DOI: 10.19082/3816.

Abdul Rahman H, Zaim SNN, Suhaimei US, Jamain AA. Prognostic factors associated with breast cancer-specific survival from 1995 to 2022: a systematic review and meta-analysis of 1,386,663 cases from 30 countries. Diseases. 2024;12(6):111,1-26.DOI: 10.3390/diseases12060111.

Akbari ME, Akbari A, Nafissi N, Shormeij Z, Sayad S, Rasaf MR, et al. Prognostic factors of recurrence (early and late) and death in breast cancer patients in Iranian women. Iran J Cancer Manag. 2016; 9(6),1-10.DOI: 10.17795/ijcp-5747.

Wishart DS. Is cancer a genetic disease or a metabolic disease? EBioMedicine. 2015;2(6):478-479.DOI: 10.1016/j.ebiom.2015.05.022.

Bao J, Zhu L, Zhu Q, Su J, Liu M, Huang W. SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer. Oncol Lett. 2016;12(4):2409-2416.DOI: 10.3892/ol.2016.4988.

Currie E, Schulze A, Zechner R, Walther TC, Farese Jr RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161.DOI: 10.1016/j.cmet.2013.05.017.

Dinarvand N, Khanahmad H, Hakimian SM, Sheikhi A, Rashidi B, Pourfarzam M. Evaluation of long-chain acyl-coenzyme A synthetase 4 (ACSL4) expression in human breast cancer. Res Pharm Sci. 2020;15(1):48-56.DOI: 10.4103/1735-5362.278714.

Dinarvand N, Khanahmad H, Hakimian SM, Sheikhi A, Rashidi B, Bakhtiari H, et al. Expression and clinicopathological significance of lipin‐1 in human breast cancer and its association with p53 tumor suppressor gene. J Cell Physiol. 2020;235(7-8):5835-5846.DOI: 10.1002/jcp.29523.

Granchi C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157: 1276-1291.DOI: 10.1016/j.ejmech.2018.09.001.

Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR, Padmavathi G, Kotoky J, et al. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2015;16(2):156-163.DOI: 10.2174/1389450115666141224125117.

Liu H, Huang X, Ye T. MiR-22 down-regulates the proto-oncogene ATP citrate lyase to inhibit the growth and metastasis of breast cancer. Am J Transl Res. 2018;10(3):659-669.PMID: 29636857.

Rochefort H, Chalbos D. The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint. Horm Cancer. 2010;1(2):63-70.DOI: 10.1007/s12672-010-0009-7.

Yen MC, Kan JY, Hsieh CJ, Kuo PL, Hou MF, Hsu YL. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance. Oncol Rep. 2017;37(6):3253-3260.DOI: 10.3892/or.2017.5610.

Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13(17): 4455,1-19.DOI: 10.3390/cancers13174455.

Milićević Z, Bajić V, Živković L, Kasapović J, Andjelković U, Spremo-Potparević B. Identification of p53 and its isoforms in human breast carcinoma cells. ScientificWorldJournal. 2014;2014(1):618698,1-10.DOI: 10.1155/2014/618698.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108.DOI: 10.1038/nprot.2008.73.

Schober P, Vetter TR. Kaplan-Meier curves, log-rank tests, and Cox regression for time-to-event data. Anesth Analg. 2021;132(4):969-970.DOI: 10.1213/ANE.0000000000005358.

Chen WC, Wang CY, Hung YH, Weng TY, Yen MC, Lai MD. Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme A synthetase family in cancer. PLoS One. 2016;11(5):e0155660,1-23.DOI: 10.1371/journal.pone.0155660.

Wang YP, Lei QY. Perspectives of reprogramming breast cancer metabolism. Adv Exp Med Biol. 2017;1026:217-232.DOI: 10.1007/978-981-10-6020-5_10.

Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, et al. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Res. 2016;76(8):2406-2418.DOI: 10.1158/0008-5472.CAN-15-1646.

Ye X, Zhang Y, Wang X, Li Y, Gao Y. Tumor-suppressive functions of long-chain acyl-CoA synthetase 4 in gastric cancer. IUBMB Life. 2016;68(4):320-327. DOI: 10.1002/iub.1486.

Nuzzo PV, Rodrigues S, Ribeiro CF, Teixeira IF, Nicolo’Fanelli G, Bleve S, et al. Targeting cancer metabolism: therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol Hematol. 2025;214:104910.DOI: 10.1016/j.critrevonc.2025.104910.

Sun X, Zhao X, Wang S, Liu Q, Wei W, Xu J, et al. The pathological significance and potential mechanism of ACLY in cholangiocarcinoma. Front Immunol. 2024;15:1477267,1-15.DOI: 10.3389/fimmu.2024.1477267.

Uchihara D, Shimajiri S, Harada Y, Kumamoto K, Oe S, Miyagawa K, et al. Long-chain fatty acyl CoA synthetase 4 expression in pancreatic cancer:a marker for malignant lesions and prognostic indicator for recurrence. Diagn Pathol. 2025;20(1):59,1-12.DOI: 10.1186/s13000-025-01659-6.

Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748,1-9.DOI: 10.1155/2014/852748.

Beheshti Isfahani M, Mahnam K, Seyedhosseini-Ghaheh H, Sadeghi HMM, Khanahmad H, Akbari V, et al. Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment. Res Pharm Sci. 2023;18(6):626-37.DOI: 10.4103/1735-5362.389950.

Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2): 111-137.DOI: 10.3322/caac.20003.

Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol. 1992;49(4):209-212.DOI: 10.1002/jso.2930490402.

Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993;24(6):584-589.DOI: 10.1016/0046-8177(93)90236-a.

Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W, Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal. 2012;2012(1):941259,1-6.DOI: 10.1100/2012/941259.

Baroš IV, Tanasković N, Pellas U, Eri Ž, Tadić Latinović L, Tot T. Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients. Bosn J Basic Med Sci. 2019;19(3):242-248.DOI: 10.17305/bjbms.2019.3970.

Wan D, Zhang Y, Yu Q, Li F, Zhuo J. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression. Pathol Res Pract. 2021;227:153619.DOI: 10.1016/j.prp.2021.153619.

Han S, Park S, An J, Yang JY, Chung JW, Kim YJ, et al. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. Sci Rep. 2020;10(1):5270,1-10.DOI: 10.1038/s41598-020-61567-1.

Sujarittanakarn S, Himakhun W, Worasawate W, Prasert W. The case-to-case comparison of hormone receptors and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Asian Pac J Cancer Prev. 2020;21(6):1559-1565.DOI: 10.31557/APJCP.2020.21.6.1559.

LaBoy C, Siziopikou KP, Rosen L, Blanco LZ, Jr., Pincus JL. Clinicopathologic features of unexpectedly HER2-positive breast carcinomas: an institutional experience. Pathol Res Pract. 2021;222:153441,1-7.DOI: 10.1016/j.prp.2021.153441


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.